Adverse events ‐ conjunctival blanching during study period · people with glaucoma receiving LTP
1 finding from 1 review
Adverse events · any physician, and any patient treated for chronic diseases with long‐term medication use
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: important adverse events · seriously mentally ill people in hospital
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ( · clinical diagnosis of depression
1 finding from 1 review
Adverse events · women with uterine fibroids
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse events · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults with cystic fibrosis
1 finding from 1 review
no estimate extracted
1 study · 6 participants
Very low
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Very low
Adverse serious events (any) (number of participants) · patients with opioid dependence
It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).
1 finding from 1 review
Adverse events · adults with cystic fibrosis
1 finding from 1 review
Adverse events Length of · and
It is very uncertain whether summary of findings: General medication review changes adverse events Length of compared with usual care (very low certainty).
1 finding from 1 review
Intervention not reported
Behavioural outcome: adherence to medication or composite outcome (medication adherence and rate of adverse events) ATCS Plus versus usual care · patients with various conditions or at risk of low adherence to medication or laboratory tests
1 finding from 1 review
Participants with at least some Side Effects · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review